{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:27:57Z","timestamp":1791160077933,"version":"4.1.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T00:00:00Z","timestamp":1400457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0097803","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T16:30:38Z","timestamp":1400517038000},"page":"e97803","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00875446","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vincent","family":"Meininger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Corse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Al-Sarraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rix Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Caress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit","family":"Cudkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Nigel","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Milleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Shefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arseniy","family":"Lavrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Overend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alienor","family":"Berges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bams","family":"Abila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Meno-Tetang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wurthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0896-6273(00)81108-3","article-title":"From Charcot to SOD1: mechanisms of selective motor neuron death in ALS","volume":"24","author":"DW Cleveland","year":"1999","journal-title":"Neuron"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","article-title":"Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"73","author":"RG Miller","year":"2009","journal-title":"Neurology"},{"key":"ref3","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"3","author":"RG Miller","year":"2012","journal-title":"Cochrane Database Syst Rev (Online)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jnnp.2009.188151","article-title":"Motor neuron disease: the bare essentials","volume":"9","author":"K Talbot","year":"2009","journal-title":"Pract Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/01.wnl.0000172911.39167.b6","article-title":"Prevalence and patterns of cognitive impairment in sporadic ALS","volume":"65","author":"GM Ringholz","year":"2005","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1474-4422(13)70036-X","article-title":"Controversies and priorities in amyotrophic lateral sclerosis","volume":"12","author":"MR Turner","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0959-4388(96)80103-6","article-title":"Therapeutic horizons for amyotrophic lateral sclerosis","volume":"6","author":"JD Rothstein","year":"1996","journal-title":"Curr Opin Neurobiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1007\/s00018-013-1415-0","article-title":"Therapeutic neuroprotective agents for amyotrophic lateral sclerosis","volume":"70","author":"RS Pandya","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?","volume":"17","author":"MC Bellingham","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.conb.2004.01.004","article-title":"Nogo and axon regeneration","volume":"14","author":"ME Schwab","year":"2004","journal-title":"Curr Opin Neurobiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrn2936","article-title":"Functions of Nogo proteins and their receptors in the nervous system","volume":"11","author":"ME Schwab","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1006\/nbdi.2002.0522","article-title":"Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis","volume":"10","author":"L Dupuis","year":"2002","journal-title":"Neurobiol Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.20420","article-title":"Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity","volume":"57","author":"N Jokic","year":"2005","journal-title":"Ann Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ana.21122","article-title":"Muscle Nogo-a expression is a prognostic marker in lower motor neuron syndromes","volume":"62","author":"P-F Pradat","year":"2007","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.21187","article-title":"Muscle Nogo-A: a marker for amyotrophic lateral sclerosis or for denervation?","volume":"62","author":"S T\u00e5gerud","year":"2007","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1044-7431(02)00036-2","article-title":"Nogo (Reticulon 4) expression in innervated and denervated mouse skeletal muscle","volume":"22","author":"C Magnusson","year":"2003","journal-title":"Mol Cell Neurosci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.21245","article-title":"Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis","volume":"62","author":"V Askanas","year":"2007","journal-title":"Ann Neurol"},{"key":"ref18","first-page":"116","article-title":"Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease","volume":"25","author":"S Wojcik","year":"2006","journal-title":"Acta Myol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.embor.7400826","article-title":"The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model","volume":"7","author":"N Jokic","year":"2006","journal-title":"EMBO Rep"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.expneurol.2003.10.004","article-title":"Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man","volume":"185","author":"LR Fischer","year":"2004","journal-title":"Exp Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.mcn.2006.03.007","article-title":"Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A","volume":"32","author":"O Weinmann","year":"2006","journal-title":"Mol Cell Neurosci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"BR Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"JM Cedarbaum","year":"1999","journal-title":"J Neurological Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/17482960903486083","article-title":"Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis","volume":"11","author":"M Sanjak","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/01.WNL.0000095961.66830.03","article-title":"A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis","volume":"61","year":"2003","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0b013e318225aabf","article-title":"Multipoint incremental motor unit number estimation as an outcome measure in ALS","volume":"77","author":"JM Shefner","year":"2011","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/nm.2579","article-title":"The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis","volume":"17","author":"M Cudkowicz","year":"2011","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial","volume":"12","author":"ME Cudkowicz","year":"2013","journal-title":"Lancet Neurol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0097803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:55:40Z","timestamp":1540202140000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0097803"}},"subtitle":[],"editor":[{"given":"Hiroyoshi","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,19]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0097803","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,19]]}}}